Research and Markets: Fibrin Stabilizing Factor Deficiency (Factor XIII Deficiency) Global Clinical Trials Review, H2, 2015

DUBLIN--()--Research and Markets (http://www.researchandmarkets.com/research/dq96nz/fibrin) has announced the addition of the "Fibrin Stabilizing Factor Deficiency (Factor XIII Deficiency) Global Clinical Trials Review, H2, 2015" report to their offering.

This new report provides an overview of Fibrin Stabilizing Factor Deficiency (Factor XIII Deficiency) clinical trials scenario. It includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type.

Clinical Trial Reports are generated using a proprietary database - Pharma eTrack Clinical trials database. These trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe and the trials database undergoes periodic update by dynamic process.

The report provides:

  • A snapshot of the global clinical trials landscape.
  • Top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status.
  • A review of top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company.
  • All the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment.
  • Enrollment trends for the past five years.
  • Latest news for the past three months.

Reasons to buy:

  • Assists in formulating key business strategies with regards to investment.
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost.
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities.
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market.
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials.
  • Facilitates clinical trial assessment of the indication on a global, regional and country level.

Companies Mentioned:

  • Novo A/S
  • CSL Limited

For more information visit http://www.researchandmarkets.com/research/dq96nz/fibrin

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Clinical Trials, Hematological

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Clinical Trials, Hematological